VivoSeq
Immunology

Lupus Erythematosus

10

Pipeline Programs↗

1

Active Trials↗

12

Companies Involved↗

Lupus Erythematosus is an early-stage landscape with 10 programs across 12 companies. The most active players are EMD Serono, Alnylam Pharmaceuticals, Metro International Biotech, LLC. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2M

Metro International Biotech, LLC

1 program

Phase 2V

Vor Biopharma

1 program

Phase 2Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

9 of 11 classified programs — the dominant modality here.

18%ALL OTHERSProtein / enzyme218%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 86% of 14 pipeline programs.

Analysis

Trial Status

8

clinical trials

Completed4 · 50%
Unknown status2 · 25%
Withdrawn1 · 13%
Recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)
Recruiting·EMD Serono Research & Development Institute, Inc. logoEMD Serono Research & Development Institute, Inc.·Phase 3·NCT07355218·202 enrolled
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
Completed·—·Phase 3·NCT00065806·221 enrolled
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
Completed·Pfizer logoPfizer·Phase 2·NCT01405196·183 enrolled
Study of Anti-Malarials in Incomplete Lupus Erythematosus
Completed·MMilton S. Hershey Medical Center·Phase 2·NCT03030118·187 enrolled
Study of Methotrexate in Lupus Erythematosus
Completed·UUniversity Health Network, Toronto·Phase 3·NCT00470522·86 enrolled
Doxycycline Outcomes in Lupus Erythematosus
Withdrawn·JJohns Hopkins University·Phase 4·NCT01014260
Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia
Unknown status·—·Phase 2·NCT05929248·64 enrolled
Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus
Unknown status·SSecond Xiangya Hospital of Central South University·Phase 2·NCT03260166·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)